Focal Epilepsy Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Focal Epilepsy remains an active clinical development field. The field is increasingly separating symptomatic benefit from disease modification, while enrichment, digital measures and fluid or imaging biomarkers reshape trial design. The PatSnap evidence set used here contains 244 matched trial records and 309 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| JPRN-jRCTs052260106 | Intervention not normalized | Early Phase 1; 募集中 | Sponsor not listed | Japan | Comparisons of EEG activity changes between active transcranial static magnetic field stimulation (tSMS) and sham stimulation will be performed during intracranial electrode monitoring, including analyses of epileptiform discharge frequency, EEG amplitude, frequency analysis, and cortico-cortical evoked potentials (CCEPs).; 頭蓋内電極留置中のtSMS 本刺激介入とシャム刺激介入における脳波での活動変化の比較（てんかん性放電の頻度、脳波振幅の分析、周波数解析、CCEP解析）を行う。 | 2030-03-31 |
| CTR20262517 | GA-002 | Phase 1/2; 进行中 （尚未招募） | GenAns Biotechnology Co., Ltd | China | (试验用药品给药后24周); (有效性观察期第 9-12 周) | Timing not listed |
| NCT07680842 | Intervention not normalized | Not Applicable; Recruiting | The University of California, San Francisco | United States | Seizure Frequency (Seizure counts will be obtained daily for at least 1 month prior to the first…) | 2027-06-01 |
| NCT07656857 | Intervention not normalized | Not Applicable; Recruiting | Beijing Tiantan Hospital | China | Seizure Freedom Rate at 6 Months After Surgery (From surgery to 6 months postoperatively) | 2028-07-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures (Phase 2): the indexed record reports Long episodes of seizure(median percent change fr baseline, 1-4 weeks) = -74.7 %.
- Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 (Phase 3): the indexed record reports FOS frequency(median percent change, at month 1) = -69.8 %.
- Efficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind, placebo-controlled, multicenter study in a multinational Asian population (Phase 3): the indexed record reports TEAE = The most common cenobamate-related treatment-emergent adverse events (≥20 %) were dizziness and somnolence.; TEAE = The most common cenobamate-related treatment-emergent adverse events (≥20 %) were dizziness and somnolence.; TEAE = The most common cenobamate-related treatment-emergent adverse events (≥20 %) were dizziness and somnolence..
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including GA-002 (Phase 1/2). Company & Deal Intelligence records identify sponsor context for GenAns Biotechnology Co., Ltd, The University of California, San Francisco, Beijing Tiantan Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Validated biomarkers that bridge biological activity to meaningful function.
- Longer follow-up that distinguishes transient symptom change from altered disease trajectory.
- Decentralized and digital measures that reduce noise without increasing patient burden.
- Trials designed around genetically or biologically defined subgroups.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Focal Epilepsy has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
